Evidence map›Paper›PMID 26801398›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2016

Characterization of the Discriminative Stimulus Effects of a NOP Receptor Agonist Ro 64-6198 in Rhesus Monkeys.

Phillip A Saccone, Kathy A Zelenock, Angela M Lindsey, Agnieszka Sulima, Kenner C Rice, Eric P Prinssen, Jürgen Wichmann, James H Woods

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Effects of NOP-Related Ligands in Nonhuman Primates.Handbook of experimental pharmacology · 2019
    Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Phillip A SacconeDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (P.A.S., K.A.Z., A.M.L., J.H.W.); National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (A.S., K.C.R.); and Hoffman- La Roche Ltd., Basel, Switzerland (E.P.P., J.W.) sacconep@umich.edu.
Kathy A ZelenockDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (P.A.S., K.A.Z., A.M.L., J.H.W.); National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (A.S., K.C.R.); and Hoffman- La Roche Ltd., Basel, Switzerland (E.P.P., J.W.).
Angela M LindseyDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (P.A.S., K.A.Z., A.M.L., J.H.W.); National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (A.S., K.C.R.); and Hoffman- La Roche Ltd., Basel, Switzerland (E.P.P., J.W.).
Agnieszka SulimaDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (P.A.S., K.A.Z., A.M.L., J.H.W.); National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (A.S., K.C.R.); and Hoffman- La Roche Ltd., Basel, Switzerland (E.P.P., J.W.).
Kenner C RiceDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (P.A.S., K.A.Z., A.M.L., J.H.W.); National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (A.S., K.C.R.); and Hoffman- La Roche Ltd., Basel, Switzerland (E.P.P., J.W.).
Eric P PrinssenDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (P.A.S., K.A.Z., A.M.L., J.H.W.); National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (A.S., K.C.R.); and Hoffman- La Roche Ltd., Basel, Switzerland (E.P.P., J.W.).
Jürgen WichmannDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (P.A.S., K.A.Z., A.M.L., J.H.W.); National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (A.S., K.C.R.); and Hoffman- La Roche Ltd., Basel, Switzerland (E.P.P., J.W.).
James H WoodsDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (P.A.S., K.A.Z., A.M.L., J.H.W.); National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (A.S., K.C.R.); and Hoffman- La Roche Ltd., Basel, Switzerland (E.P.P., J.W.).
National Institute on Alcohol Abuse and Alcoholism · USUniversity of Michigan–Ann Arbor · USNational Institute on Drug Abuse · US

Funding

Medicinal Chemistry of Drugs Acting on Central and Peripheral Opioid ReceptorsZIADA000527 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI RICE, KENNER · 2009 to 2025
$23.2M
NIDA Training Program in Neuroscience-Administrative SupplementT32DA007281 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Shelly Beth Flagel · 1995 to 2026
$5.7M
Evaluating the NOP receptor as a novel target for pain control: characterizing tF31DA038488 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SACCONE, PHILLIP ANTHONY · 2014 to 2015
$60k
NIDA NIH HHS F31 DA038488NIDA NIH HHS F31-DA038488NIDA NIH HHS T32 DA007281NIDA NIH HHS T32-DA007281
6 · The paper itself

Abstract

Nociceptin/orphanin FQ receptor (NOP) agonists have been reported to produce antinociceptive effects in rhesus monkeys with comparable efficacy to μ-opioid receptor (MOP) agonists, but without their limiting side effects. There are also known to be species differences between rodents and nonhuman primates (NHPs) in the behavioral effects of NOP agonists. The aims of this study were the following: 1) to determine if the NOP agonist Ro 64-6198 could be trained as a discriminative stimulus; 2) to evaluate its pharmacological selectivity as a discriminative stimulus; and 3) to establish the order of potency with which Ro 64-6198 produces discriminative stimulus effects compared with analgesic effects in NHPs. Two groups of rhesus monkeys were trained to discriminate either fentanyl or Ro 64-6198 from vehicle. Four monkeys were trained in the warm-water tail-withdrawal procedure to measure antinociception. Ro 64-6198 produced discriminative stimulus effects that were blocked by the NOP antagonist J-113397 and not by naltrexone. The discriminative stimulus effects of Ro 64-6198 partially generalized to diazepam, but not to fentanyl, SNC 80, ketocyclazocine, buprenorphine, phencyclidine, or chlorpromazine. Fentanyl produced stimulus effects that were blocked by naltrexone and not by J-113397, and Ro 64-6198 did not produce fentanyl-appropriate responding in fentanyl-trained animals. In measures of antinociception, fentanyl, but not Ro 64-6198, produced dose-dependent increases in tail-withdrawal latency. Together, these results demonstrate that Ro 64-6198 produced stimulus effects in monkeys that are distinct from other opioid receptor agonists, but may be somewhat similar to diazepam. In contrast to previous findings, Ro 64-6198 did not produce antinociception in the majority of animals tested even at doses considerably greater than those that produced discriminative stimulus effects.

Indexed as

Analgesics, OpioidAnimalsBenzimidazolesConditioning, OperantDiazepamDiscrimination, PsychologicalDose-Response Relationship, DrugFemaleFentanylGABA ModulatorsImidazolesMacaca mulattaMaleNaltrexoneNarcotic AntagonistsNociceptin ReceptorAnalgesics, OpioidBenzimidazolesDiazepamFentanylGABA ModulatorsImidazolesJ 113397NaltrexoneNarcotic AntagonistsNociceptin ReceptorPiperidinesReceptors, OpioidRo 64-6198Spiro Compounds

Identifiers

PMID26801398
PMCPMC4809320
OpenAlexW2258284584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.